Development Of Platelet Storage Lesion Research Articles

Liposomal Resveratrol Alleviates Platelet Storage Lesion via Antioxidation and the Physical Buffering Effect.

Platelet transfusion is essential in the treatment of platelet-related diseases and the prevention of bleeding in patients with surgical procedures. Platelet transfusion efficacy and shelf life are limited mainly by the development of platelet storage lesion (PSL). Mitigating PSL is the key to prolonging the platelet shelf life and reducing wastage. Excess intracellular reactive oxygen species (ROS) are one of the main factors causing PSL. In this study, we explored a nanomedicine strategy to improve the quality and functions of platelets in storage. Resveratrol (Res), a natural plant product, is known for its antioxidative effect. However, medical applications of Res are limited due to its low water solubility and stability. Therefore, we used a resveratrol-loaded liposomal system (Res-Lipo) to better utilize the antioxidant effect of the drug. This study aimed to evaluate the effect of Res-Lipo on platelet oxidative stress and alleviation of PSL during the storage time. Res-Lipo scavenged intracellular ROS and inhibited platelet apoptosis and activation during storage. Res-Lipo not only maintained mitochondrial function but also improved platelet aggregation in response to adenosine 5'-diphosphate. These results revealed that Res-Lipo ameliorated PSL and prolonged the platelet survival time in vivo. The strategy provides a potential method for extending the platelet storage time and might be considered a potential and safe additive to alleviate PSL.

RETRACTED: Platelet storage lesion: Current proteomics approach

The platelet storage lesion (PSL) is best defined as the sum of all deleterious changes leading to progressive damage in platelet structure and function that arise from the time blood is drawn from a donor to the time platelets are transfused to a recipient. Proteomics, the analysis of all proteins of a system at a defined state, has gained increasing interest in hematology as a diagnostic tool. The application of proteomics in transfusion medicine holds promise to revolutionize quality assessment and therapeutic monitoring. The potential of proteomics as a viable tool for the identification of the PSL has since increased dramatically with the development of mass spectrometry and has required the development of quantitative proteomic techniques such as differential gel electrophoresis, isotope-coded affinity tagging, and isotope tagging for relative and absolute quantitation. In principle, two main areas in the field of proteomics have been developed, each of them having its pros and cons. These fields are “profiling” and “functional” proteomics. With the recent implementation of pathogen reduction technologies (PRT) a new dimension of challenges has appeared on the horizon. The treatment of platelet concentrates with either UV-A and a photo sensitizer or UV-C revealed acceleration of PSL development. In conclusion, proteomics thus provides an excellent tool to decode complex processes by identifying novel platelet-expressed proteins and analysing functional changes of the platelet proteome. These recent results suggest that protein kinases might represent one important group of proteins involved in the development of PSL and provide a potential target for inhibition in order to reduce development of PSL. Bacterial risk receives and deserves a lot of attention when it comes to extension of platelet storage; however, determining the quality of platelets during storage needs to be treated with equal importance. As a platelet's life span is 7–10 days, extension of the platelet's shelf life by 2–3 days would improve platelet inventory and efforts of donor recruitment tremendously, as well as to the overall cost of provision of this blood product to patients.

The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.

The Mirasol Pathogen Reduction Technology system for platelets and plasma uses riboflavin and UV light to introduce irreparable lesions into nucleic acids thereby inhibiting pathogen and white blood cell replication and reducing the load of infectious pathogens. The aim of the present study was to evaluate low plasma buffy coat platelet concentrates obtained from the OrbiSac System and to examine the effects on the development of platelet storage lesion during storage in platelet additive solution. Twenty buffy coat platelet concentrates were generated by pooling five individual units using the OrbiSac System. Riboflavin was added during the final pooling step, and the units were exposed to UV light. The bag was removed after the target energy of 6.24 J/mL had been delivered and 150 mL of platelet additive solution were added prior to storage. Platelet quality was assessed by pH, swirl, CD62P expression, lactate dehydrogenase, lactate production and glucose consumption rates over 7 days of storage. Buffy coat platelet concentrates generated on the OrbiSac contained an average 3.5 +/- 0.6 x 10(11) platelets at a concentration of 2976+/- 406 x 10(6)/mL. After addition of 150 mL platelet additive solution the storage concentration was 1043 +/- 148x 10(6)/mL. Values obtained for pH, lactate production and glucose consumption rates were all within the limits of previously established correlations between in vitro cell quality and in vivo performance of Pathogen Reduction Technology-treated platelets in plasma. In vitro studies show that OrbiSac-derived platelets treated with the Mirasol Pathogen Reduction Technology system preserve adequate function, which would indicate acceptable in vitro viability.